Emerging and Investigational Weight-Loss Medications
Obesity drug development is moving quickly, but promising trial results do not make a medicine FDA-approved, commercially available or appropriate for routine prescribing.

Current status overview
Retatrutide
Investigational triple-receptor agonist in phase 3 studies.
CagriSema
Investigational cagrilintide/semaglutide combination studied in phase 3.
MariTide
Investigational antibody-peptide conjugate in a phase 3 program.
Aleniglipron
Investigational oral small-molecule GLP-1 agonist in clinical trials.
Foundayo
FDA-approved oral orforglipron—not an investigational drug.
Research-product safety
Why products sold online “for research only” are not patient treatment.
How W8MD can help now
Patients do not need to wait for a future drug to receive evidence-based care. W8MD can compare currently approved weight-loss medications, nutrition, sleep treatment and non-medication plans using medical history, prior attempts, preferences, coverage and sustainable cost.
Discuss currently available options with W8MD
Brooklyn: 718-946-5500 · Northeast Philadelphia: 215-676-2334
Use the form only for a non-urgent callback request. Do not submit private medical, insurance, financial or other sensitive information.
Status reviewed September 4, 2026. Recheck FDA labeling and ClinicalTrials.gov before relying on this page.

